Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Si

Showing results (191-200 of 230) with videos related to

Pageof 23
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathwayLili Mao, Jie Dai, Yabin Cao, et al.
Frontiers in Oncology|July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal MelanomaLirui Tang, Xiaoting Wei, Caili Li, et al.
Theranostics|March 15, 2019
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK PathwaysMeng Ma, Jie Dai, Huan Tang, et al.
Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Theranostics|May 13, 2022
Erratum: MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: ErratumMeng Ma, Jie Dai, Huan Tang, et al.
The British Journal of Dermatology|January 18, 2022
Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective studyXiaoting Wei, Di Wu, Yu Chen, et al.
Journal of Hematology & Oncology|January 16, 2019
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsBixia Tang, Xieqiao Yan, Xinan Sheng, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Pageof 23

Showing results (191-200 of 230) with videos related to

Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|March 26, 2021
Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathwayLili Mao, Jie Dai, Yabin Cao, et al.
Frontiers in Oncology|July 18, 2022
Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal MelanomaLirui Tang, Xiaoting Wei, Caili Li, et al.
Theranostics|March 15, 2019
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK PathwaysMeng Ma, Jie Dai, Huan Tang, et al.
Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Theranostics|May 13, 2022
Erratum: MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: ErratumMeng Ma, Jie Dai, Huan Tang, et al.
The British Journal of Dermatology|January 18, 2022
Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective studyXiaoting Wei, Di Wu, Yu Chen, et al.
Journal of Hematology & Oncology|January 16, 2019
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsBixia Tang, Xieqiao Yan, Xinan Sheng, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Pageof 23